KOVERA LABS · CLIENT RECORD·SNAPSHOT 2026-08-02
Orbitrex Peptides: 14 Kovera certificates.
The lab's record shows 14 certificates printed for Orbitrex Peptides, analysed between 26 Apr 2026 and 24 May 2026, covering 11 products. Median HPLC purity is 99.78%. Kovera graded 14 as a pass and 0 as a fail.
14
certificates
99.78%
median purity
11
products
0
lab verdict: fail
0
failure rules met
What the record shows
RETRIEVED 2 AUGUST 2026None of the 14 certificates meets our failure rules: no lab fail, no unconfirmed identity, no purity under 95% and no content under 90% of the label. 5 measured more than 110% of the label, which Kovera does not grade as a fail.
A certificate covers the sample the client sent, and the client decides which results go public. The figures are as published on 2 August 2026; check the lab's verify page for the current version before you rely on one.
Products tested
11 AS PRINTEDNAD+ · 2Pinealon · 2Retatrutide · 2BPC-157 · 1CJC-1295 (No DAC)/Ipamorelin · 1Epithalon · 1MOTS-c · 1SS-31 · 1Tesamorelin · 1Thymosin alpha-1 · 1Tirzepatide · 1
Every certificate
NEWEST FIRST · 14 ROWS| Report | Product | Lot | Purity | % of label | Analysed | Result | Check |
|---|---|---|---|---|---|---|---|
| KVR-2026-B44040 | Thymosin alpha-1 | TA110626 | 98.234% | 109.7%10.97 of 10 mg | 24 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-73FAA0 | Epithalon | EPI10626 | 99.629% | 114.4%11.44 of 10 mg | 24 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-4CFDF3 | CJC-1295 (No DAC)/Ipamorelin | CJP10626 | 99.762% | 104.0%10.4 of 10 mg | 24 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-CE6271 | Tesamorelin | TS10626 | 99.343% | 102.4%10.24 of 10 mg | 20 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-C6E15B | Retatrutide | 3G36626 | 98.836% | 119.5%43.02 of 36 mg | 20 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-88D259 | SS-31 | MTP10626 | 98.972% | 107.9%10.79 of 10 mg | 20 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-1830D5 | BPC-157 | BPC10626 | 99.538% | 98.6%9.86 of 10 mg | 20 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-EC7DC3 | NAD+ | NAD500526A | 99.819% | 101.5%507.64 of 500 mg | 13 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-92673A | NAD+ | NAD500526 | 99.836% | 105.6%527.78 of 500 mg | 13 May 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-5BE84B | MOTS-c | MOT10526 | 99.948% | 114.4%11.44 of 10 mg | 13 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-144FA6 | Retatrutide | 3G10526US | 99.816% | 114.8%11.48 of 10 mg | 9 May 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-E33957 | Tirzepatide | 2G10526 | 99.863% | 116.7%11.67 of 10 mg | 26 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-0CDB39-S90 | Pinealon | Pin10526 | 99.798% | 98.8%9.88 of 10 mg | 26 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-0CDB39 | Pinealon | Pin10526 | 99.853% | 98.8%9.88 of 10 mg | 26 Apr 2026 | PASS | Kovera ↗our verifier → |